BIOLIFE SOLUTIONS INC

Listed Company

BLFSCIK 0000834365NasdaqLarge AcceleratedElectromedical & Electrotherapeutic ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-4.59M

Total Assets

—

Equity

—

Shares Out

48.86M

Op. Cash Flow

$20.11M

BLFS$29.11+35.84% · past yearDBEQ Basic

Daily closing prices

Business

BioLife Solutions Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy industry. The company offers biopreservation media (HypoThermosol® FRS and CryoStor® Freeze Media), human platelet lysate media, cryogenic containers, automated cell-processing and thawing devices, and related products designed to preserve cell viability and extend shelf-life during manufacturing and distribution. BioLife operates as a single bioproduction business segment serving cell and gene therapy manufacturers globally through direct sales and regional distribution partnerships, with manufacturing facilities in Bothell, Washington and Indianapolis, Indiana.

Summary from 10-K filed 2026-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	96	75	68	76	119
Cost of revenue	34	25	27	—	—
Gross profit	62	50	41	—	—
General and administrative	46	41	43	33	34
Sales and marketing	10	9	11	12	14
Research and development	8	5	6	9	12
IPR&D expense	16	0	0	—	—
Intangible asset amortization	263,000	263,000	1	4	8
Change in fair value of contingent consideration	0	0	−2	−5	3
Total operating expenses	79	55	59	82	154
Operating loss	−17	−4	−17	−6	−35
Interest income (expense), net	3	−766,000	−1	−284,000	−485,000
Other income	2	494,000	1	662,000	289,000
Change in fair value of investments	0	−4	0	697,000	0
Gain on settlement of Global Cooling escrow	0	0	5	0	0
Total other income (expense), net	5	−4	5	1	6
Loss from continuing operations before income tax expense (benefit)	−12	−9	−12	−5	−29
Income tax expense (benefit)	49,000	−38,000	−64,000	5	20
Loss from continuing operations	−12	−9	−12	388,000	—
Income (loss) from discontinued operations before income tax expense	8	−11	−56	−140	—
Income tax expense	0	132,000	233,000	−214,000	—
Income (loss) from discontinued operations	8	−11	−56	−140	—
Net loss	−5	−20	−68	−140	−9
Continuing operations (in dollars per share)	−0.25	−0.19	−0.28	0.01	—
Discontinuing operations (in dollars per share)	0.16	−0.25	−1.27	−3.3	—
Net loss (in dollars per share)	−0.09	−0.44	−1.55	−3.29	−0.23
Continuing operations (in dollars per share)	−0.25	−0.19	−0.28	0.01	—
Discontinuing operations (in dollars per share)	0.15	−0.25	−1.27	−3.26	—
Net loss (in dollars per share)	−0.1	−0.44	−1.55	−3.25	−0.23
Basic (in shares)	48	46	44	42	39
Diluted (in shares)	49	46	44	43	39

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	33	92	28	19	70
Available-for-sale securities, current portion	56	9	16	43	0
Accounts receivable, trade, net of allowance for credit losses of $22 and $152 as of December 31, 2025 and December 31, 2024, respectively	8	8	8	34	23
Inventories	30	29	27	35	28
Prepaid expenses and other current assets	10	6	5	7	5
Current assets, discontinued operations	0	5	37	—	—
Total current assets	137	149	121	138	126
Property and equipment, net	15	6	6	24	18
Operating lease right-of-use assets, net	7	11	7	15	19
Other assets	3	373,000	—	—	—
Available-for-sale securities, long term	31	5	548,000	1	0
Equity investments	0	995,000	5	—	—
Intangible assets, net	4	6	12	32	152
Goodwill	209	209	212	225	58
Long-term assets, discontinued operations	0	14	43	—	—
Total assets	406	399	413	450	554
Accounts payable	1	3	2	15	15
Accrued expenses and other current liabilities	12	12	9	10	7
Sales taxes payable	2	4	4	4	3
Lease liabilities, operating, current portion	2	1	1	3	3
Debt, current portion	5	11	6	2	862,000
Current liabilities, discontinued operations	0	616,000	19	—	—
Total current liabilities	23	33	42	45	43
Lease liabilities, operating, long-term	11	13	9	15	16
Debt, long-term	0	5	18	24	6
Deferred tax liabilities	189,000	124,000	114,000	250,000	5
Other long-term liabilities	171,000	0	0	10,000	42,000
Long-term liabilities, discontinued operations	0	78,000	7	—	—
Total liabilities	34	51	75	86	76
Commitments and contingencies (Note 11)	—	—	—	—	—
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024	0	0	0	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 48,198,928 and 46,906,765 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	48,000	47,000	45,000	43,000	42,000
Additional paid-in capital	711	684	653	612	585
Accumulated other comprehensive loss, net of taxes	132,000	24,000	−345,000	−679,000	−282,000
Accumulated deficit	−340	−335	−315	−247	−107
Total shareholders equity	372	349	338	364	478
Total liabilities and shareholders equity	406	399	413	450	554

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Impairment of intangible assets	0	0	6	110	0
Impairment of long-lived assets	0	0	10	0	0
Gain on settlement of Global Cooling escrow	0	0	−5	0	—
Depreciation	2	5	7	7	5
Amortization of intangible assets	2	4	5	10	—
Amortization of loan costs	0	0	13,000	18,000	121,000
Stock-based compensation	23	31	33	25	14
Non-cash lease expense	2	424,000	404,000	3	—
Deferred income tax expense (benefit)	65,000	−64,000	−62,000	−5	−20
Change in fair value of equity investment and other	−983,000	4	0	−697,000	0
Accretion of investments	−736,000	−474,000	−1	−447,000	0
Loss on disposal of assets held for rent, net	510,000	567,000	594,000	773,000	609,000
Loss on disposal of property and equipment, net	11,000	154,000	633,000	745,000	482,000
Net gain on disposal of subsidiaries	−10	−16	0	0	—
Accounts receivable, trade, net	264,000	−3	15	−11	−10
Inventories	−1	781,000	−9	−7	114,000
Prepaid expenses and other current assets	−3	−2	137,000	26,000	3
Accounts payable	−2	26,000	−8	414,000	2
Accrued expenses and other current liabilities	−1	6	2	2	−4
Sales taxes payable	−2	−973,000	1	2	1
Warranty liability	5,000	−528,000	−454,000	−1	—
Other	264,000	−258,000	97,000	−260,000	−230,000
Net cash provided by (used in) operating activities	20	8	−12	−8	−5
Purchases of property and equipment	−9	−3	−6	−10	−8
Purchases of assets held for rent	−886,000	−2	−5	−4	−6
Proceeds from sale of available-for-sale securities	7	4	3	420,000	0
Maturities of available-for-sale securities	35	18	53	9	0
Investment in available-for-sale securities	−114	−18	−27	−53	0
Purchases of intangible assets	0	−300,000	0	0	—
Investment in IPR&D	−10	0	0	—	—
Investment in convertible promissory note	−2	0	0	—	—
Proceeds from sale of divested entities	24	73	0	0	—
Payments on divestiture of Global Cooling	0	−13	0	0	—
Net cash (used in) provided by investing activities	−72	58	18	−58	−13
Payments on term loan	−10	−5	−300,000	−2	0
Payments on equipment loans	0	−2	−198,000	−498,000	−214,000
Issuance of common stock	0	0	10	0	0
Proceeds from exercise of common stock options	18,000	202,000	507,000	323,000	1
Proceeds from financed insurance premium	0	2	3	0	0
Payments on financed insurance premium	−975,000	−2	−2	−1	−1
Other	33,000	−74,000	64,000	−337,000	−124,000
Net cash (used in) provided by financing activities	−11	−7	11	16	−3
Net (decrease) increase in cash and cash equivalents	−62	60	16	−50	−21
Effects of currency translation on cash and cash equivalents	0	0	35,000	−108,000	−23,000
Assets acquired under operating leases	0	6	880,000	243,000	7
Assets acquired under finance leases	0	0	2	0	440,000
Purchase of property and equipment not yet paid	0	107,000	359,000	478,000	197,000
Unrealized loss (gain) on available-for-sale securities	108,000	−18,000	−56,000	50,000	0
Unrealized gain on currency translation	0	0	−12,000	—	—
Non-cash acquisition of PanTHERA	5	0	0	—	—
Returned shares from settlement of Global Cooling escrow	0	0	−5	0	0
Cash interest paid	762,000	2	2	586,000	452,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is BIOLIFE SOLUTIONS INC's CIK number?

BIOLIFE SOLUTIONS INC's SEC CIK number is 0000834365 (834365). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find BIOLIFE SOLUTIONS INC's SEC filings?

All of BIOLIFE SOLUTIONS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did BIOLIFE SOLUTIONS INC last report earnings?

BIOLIFE SOLUTIONS INC (BLFS) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-032123). This is BIOLIFE SOLUTIONS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is BIOLIFE SOLUTIONS INC's most recent earnings 8-K?

BIOLIFE SOLUTIONS INC's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-032123. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View BIOLIFE SOLUTIONS INC's latest earnings 8-K →
Look up any company's CIK number →